Company intelligence / Profile preview

Marelius Biopharma Group

United Kingdom

Ownership: Private
Development stage: Other

Overview

Marelius Biopharma Group (MBG) is a UK-based company specializing in delivering training and educational services focused on regulatory compliance, aseptic practices, and manufacturing standards for the biopharmaceutical and pharmaceutical sectors. In January 2025, MBG was acquired by Argentum 47, Inc. as part of its strategy to strengthen its presence in high-growth, specialized markets in the life sciences sector.

Modalities: Not applicable (training/education provider)
Industry: Consulting

Beyond the preview

Go deeper on Marelius Biopharma Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marelius Biopharma Group.

Explore the full profile